Epidemiology of Respiratory Syncytial Virus-related Hospitalizations and the Influence of Viral Coinfections in Southern Austria in a 7-year Period.


Journal

The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858

Informations de publication

Date de publication:
01 2020
Historique:
pubmed: 28 10 2019
medline: 22 9 2020
entrez: 26 10 2019
Statut: ppublish

Résumé

The aim of this study was to determine the respiratory syncytial virus (RSV) epidemiology and to analyze the influence of risk factors and coinfections over the last years. Retrospectively all infants, children and adolescents hospitalized due to respiratory disease with positive RSV test [hospitalized for RSV infection (RSV-H)] between January 1, 2009, and December 31, 2015, at a tertiary care center in the southern part of Austria were included for analysis. Patients were all identified by a search via International Classification of Diseases and Related Health Problems, 10th Edition codes, and all medical data were collected from the local electronic databases called openMedocs. RSV tests had to prove true infection case definition. During a 7-year study period, 745 infants, children and adolescents exhibited RSV-H. Main diagnosis was bronchiolitis (70%). Nearly half of all cases (44%) were born during the first half of the RSV season (November-January), and seasonal peak of RSV-H was in January. Predominant underlying condition was history of prematurity in 15% followed by neurologic impairment (3.5%) and hemodynamically significant congenital heart disease (2.95%). Age ≤2 months and underlying conditions/morbidities were associated with more severe disease. The majority of cases (96%) had an age below 24 months, and 91% below 12 months. Viral coinfection (most common influenza virus, adenovirus and rhinovirus) was diagnosed in 37 cases (5%) resulting in a more severe course of disease. Main risk factors of coinfection were siblings and crowding. Mortality was 0.27% (2/745). Both children had coinfection with influenza A virus and were multihandicapped (15 and 20 years of age, respectively). Prematurity and underlying morbidities play a marked role in RSV-H. Viral coinfections aggravated disease with death in 2 multihandicapped adolescents.

Identifiants

pubmed: 31651808
doi: 10.1097/INF.0000000000002494
pii: 00006454-202001000-00003
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-16

Références

Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2:25–32.
Bont L, Checchia PA, Fauroux B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther. 2016;5:271–298.
Resch B, Puchas C, Urlesberger B. Respiratory syncytial virus-associated hospitalization rates in high-risk populations: an observational comparative cohort analysis. Eur J Clin Microbiol Infect Dis. 2018;37:2413–2414.
Resch B, Gusenleitner W, Mandl C, et al. Epidemiology of respiratory syncytial virus infection in Southern Austria. Pediatr Infect Dis J. 2000;19:587–588.
Simoes EA. Respiratory syncytial virus infection. Lancet. 1999;354:847–852.
Resch B, Wörner C, Özdemir S, et al. Respiratory syncytial virus associated hospitalizations in infants of 33 to 42 weeks’ gestation: does gestational age matter? Klin Padiatr. 2019;231:206–211.
Anderson EJ, Carbonell-Estrany X, Blanken M, et al. Burden of severe respiratory syncytial virus disease among 33-35 weeks’ gestational age infants born during multiple respiratory syncytial virus seasons. Pediatr Infect Dis J. 2017;36:160–167.
Resch B. Respiratory syncytial virus (RSV) prophylaxis: summary of the Austrian recommendations [German]. Pädiatrie Pädologie 2009;2:35–36.
Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 1993;329:1524–1530.
Meissner C. Acute viral bronchiolitis. New Engl J Med. 2016;374:62–72.
Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126:212–219.
Behrendt CE, Decker MD, Burch DJ, et al. International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group. Eur J Pediatr. 1998;157:215–220.
Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588–598.
Viguria N, Martínez-Baz I, Moreno-Galarraga L, et al. Respiratory syncytial virus hospitalization in children in northern Spain. PLoS One. 2018;13:e0206474.
Eriksson M, Bennet R, Rotzén-Ostlund M, et al. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. 2002;91:593–598.
Duppenthaler A, Gorgievski-Hrisoho M, Frey U, et al. Two-year periodicity of respiratory syncytial virus epidemics in Switzerland. Infection. 2003;31:75–80.
Rossi GA, Medici MC, Arcangeletti MC, et al.; Osservatorio RSV Study Group. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr. 2007;166:1267–1272.
Saravanos GL, Sheel M, Homaira N, et al. Respiratory syncytial virus-associated hospitalisations in Australia, 2006-2015. Med J Aust. 2019;210:447–453. doi: 10.5694/mja2.50159. [Epub ahead of print].
doi: 10.5694/mja2.50159.
Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132:e341–e348.
Simon A, Ammann RA, Wilkesmann A, et al.; DSM RSV Paed Study Group. Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr. 2007;166:1273–1283.
Hervás D, Reina J, Yañez A, et al. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis. 2012;31:1975–1981.
Gentile A, Lucion MF, Juarez MDV, et al. Burden of respiratory syncytial virus disease and mortality risk factors in Argentina: 18 years of active surveillance in a children’s hospital. Pediatr Infect Dis J. 2019;38:589–594.
Ghazaly M, Nadel S. Characteristics of children admitted to intensive care with acute bronchiolitis. Eur J Pediatr. 2018;177:913–920.
Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child. 2009;94:99–103.
Korsun N, Angelova S, Trifonova I, et al. Viral pathogens associated with acute lower respiratory tract infections in children younger than 5 years of age in Bulgaria. Braz J Microbiol. 2019;50:117–125.
Appak Ö, Duman M, Belet N, et al. Viral respiratory infections diagnosed by multiplex polymerase chain reaction in pediatric patients. J Med Virol. 2019;91:731–737.
Antalis E, Oikonomopoulou Z, Kottaridi C, et al. Mixed viral infections of the respiratory tract; an epidemiological study during consecutive winter seasons. J Med Virol. 2018;90:663–670.
Petrarca L, Nenna R, Frassanito A, et al. Acute bronchiolitis: Influence of viral co-infection in infants hospitalized over 12 consecutive epidemic seasons. J Med Virol. 2018;90:631–638.
Kutsaya A, Teros-Jaakkola T, Kakkola L, et al. Prospective clinical and serological follow-up in early childhood reveals a high rate of subclinical RSV infection and a relatively high reinfection rate within the first 3 years of life. Epidemiol Infect. 2016;144:1622–1633.
Mazur NI, Higgins D, Nunes MC, et al. Respiratory Syncytial Virus Network (ReSViNET) Foundation. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018;18:e295–e331.

Auteurs

Bernhard Resch (B)

From the Division of Neonatology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
Research Unit for Neonatal Infectious Diseases and Epidemiology, Medical University of Graz, Graz, Austria.

Claudia Puchas (C)

Research Unit for Neonatal Infectious Diseases and Epidemiology, Medical University of Graz, Graz, Austria.

Elisabeth Resch (E)

From the Division of Neonatology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
Research Unit for Neonatal Infectious Diseases and Epidemiology, Medical University of Graz, Graz, Austria.

Berndt Urlesberger (B)

From the Division of Neonatology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH